Alpha 2.0
Login Register
» Articles » PMID: 34383732

Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021

Overview
Journal MMWR Morb Mortal Wkly Rep
Date 2021 Aug 12
PMID 34383732
Citations 143
Authors
Alyson M Cavanaugh
Kevin B Spicer
Douglas Thoroughman
Connor Glick
Kathleen Winter
Affiliations
Soon will be listed here.
Abstract

Although laboratory evidence suggests that antibody responses following COVID-19 vaccination provide better neutralization of some circulating variants than does natural infection (1,2), few real-world epidemiologic studies exist to support the benefit of vaccination for previously infected persons. This report details the findings of a case-control evaluation of the association between vaccination and SARS-CoV-2 reinfection in Kentucky during May-June 2021 among persons previously infected with SARS-CoV-2 in 2020. Kentucky residents who were not vaccinated had 2.34 times the odds of reinfection compared with those who were fully vaccinated (odds ratio [OR] = 2.34; 95% confidence interval [CI] = 1.58-3.47). These findings suggest that among persons with previous SARS-CoV-2 infection, full vaccination provides additional protection against reinfection. To reduce their risk of infection, all eligible persons should be offered vaccination, even if they have been previously infected with SARS-CoV-2.

Citing Articles

Protection afforded by post-infection SARS-CoV-2 vaccine doses: A cohort study in Shanghai.

Zheng B, Goncalves B, Deng P, Wang W, Tian J, Liang X Elife. 2025; 13.

PMID: 39960759 PMC: 11832167. DOI: 10.7554/eLife.94990.

COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.

Chang J, Chang M, Huang S, Bosco J, McNairy M, Tukuru S Vaccine. 2024; 42(26):126260.

PMID: 39265456 PMC: 11645243. DOI: 10.1016/j.vaccine.2024.126260.

Association of Prior COVID-19 Infection with Risk of Breakthrough Infection Following Vaccination: A Cohort Study in Isfahan, Iran.

Manteghinejad A, Rasti S, Nasirian M, Javanmard S Int J Prev Med. 2024; 15:18.

PMID: 39170924 PMC: 11338365. DOI: 10.4103/ijpvm.ijpvm_173_23.

Physiological Response to the COVID-19 Vaccine: Insights From a Prospective, Randomized, Single-Blinded, Crossover Trial.

Markovic A, Kovacevic V, Brakenhoff T, Veen D, Klaver P, Mitratza M J Med Internet Res. 2024; 26():e51120.

PMID: 39083770 PMC: 11325110. DOI: 10.2196/51120.

Quantifying Disparities in COVID-19 Vaccination Rates by Rural and Urban Areas: Cross-Sectional Observational Study.

Dong W, Miao Y, Shen Z, Zhang W, Bai J, Zhu D JMIR Public Health Surveill. 2024; 10:e50595.

PMID: 39028548 PMC: 11297372. DOI: 10.2196/50595.

References
1.
Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View
2.
Deng X, Garcia-Knight M, Khalid M, Servellita V, Wang C, Morris M . Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021; 184(13):3426-3437.e8. PMC: 8057738. DOI: 10.1016/j.cell.2021.04.025. View
3.
Saadat S, Tehrani Z, Logue J, Newman M, Frieman M, Harris A . Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021; 325(14):1467-1469. PMC: 7922233. DOI: 10.1001/jama.2021.3341. View
4.
Manisty C, Otter A, Treibel T, McKnight A, Altmann D, Brooks T . Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021; 397(10279):1057-1058. PMC: 7972310. DOI: 10.1016/S0140-6736(21)00501-8. View
5.
Cevik M, Tate M, Lloyd O, Maraolo A, Schafers J, Ho A . SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021; 2(1):e13-e22. PMC: 7837230. DOI: 10.1016/S2666-5247(20)30172-5. View